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S100A12 is up-regulated in 
pulmonary tuberculosis and 
predicts the extent of alveolar 
infiltration on chest radiography: 
an observational study
Luis C. Berrocal-Almanza1,2, Surabhi Goyal1, Abid Hussain3, Tilman E. Klassert2, 
Dominik Driesch4, Zarko Grozdanovic5, Gadamm Sumanlatha3, Niyaz Ahmed6, 
Vijayalakshmi Valluri7, Melanie L. Conrad1, Nickel Dittrich1, Ralf R. Schumann1, Birgit Lala8 & 
Hortense Slevogt2
Pulmonary tuberculosis (PTB) results in lung functional impairment and there are no surrogate markers 
to monitor the extent of lung involvement. We investigated the clinical significance of S100A12 
and soluble receptor for advanced glycation end-products (sRAGE) for predicting the extent of lung 
involvement. We performed an observational study in India with 119 newly diagnosed, treatment 
naïve, sputum smear positive, HIV-negative PTB patients and 163 healthy controls. All patients were 
followed-up for six months. Sociodemographic variables and the serum levels of S100A12, sRAGE, 
esRAGE, HMGB-1, TNF-α, IFN-γ and CRP were measured. Lung involvement in PTB patients was 
assessed by chest radiography. Compared with healthy controls, PTB patients had increased serum 
concentrations of S100A12 while sRAGE was decreased. S100A12 was an independent predictor 
of disease occurrence (OR 1.873, 95%CI 1.212–2.891, p = 0.004). Under DOTS therapy, S100A12 
decreased significantly after 4 months whereas CRP significantly decreased after 2 months (p < 0.0001). 
Importantly, although CRP was also an independent predictor of disease occurrence, only S100A12 was 
a significant predictor of lung alveolar infiltration (OR 2.60, 95%CI 1.35–5.00, p = 0.004). These results 
suggest that S100A12 has the potential to assess the extent of alveolar infiltration in PTB.
Tuberculosis (TB) is a global public health problem, particularly in low-income and middle-income countries 
which account for more than 80% of the cases1. Active TB most frequently affects the lungs and its pathology is 
often characterized by an exudative reaction progressing to caseous pneumonia2. In pulmonary TB (PTB) the 
extent of tissue pathology is associated with bacillary burden and impairment of lung function2,3. Importantly, 
the extent of pulmonary affliction during active disease is also associated with long term function impairment 
which often persists after successful completion of antibiotic treatment4,5. Current strategies to diagnose and 
follow active TB are based on microbiological, clinical and radiographic examinations6. However, the extent of 
pulmonary affliction at the time of diagnosis is rarely quantified, mainly due to the lack of surrogate markers and 
standardized evaluation systems. Thus, besides the urgent need for better markers to diagnose active PTB, the 
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identification of surrogate markers for stratification of lung involvement might aid the formulation of step care 
plans to address the possibility of long-term lung impairment7.
There is increasing evidence from experimental M. tuberculosis infection in mice that the influx of neutrophils 
into the lungs is associated with necrotic lesions and increased pulmonary pathology8–10. Human S100A12 is 
predominantly expressed and secreted by activated neutrophil granulocytes11. In this regard, S100A12 is known 
to trigger a pro-inflammatory immune response by binding the multi-ligand receptor for advanced glycation 
end-products (RAGE) and activating transcription factors such as the nuclear factor (NF)-kB11–14. In addition 
to the membrane-bound full-length RAGE, two soluble RAGE forms exist; a soluble endogenous secreted form 
(esRAGE) produced by alternative splicing, and soluble cleaved RAGE (sRAGE) produced after the proteolytic 
cleavage of full-length membrane bound RAGE by metalloproteinases12,13,15–18. Notably, these soluble forms act 
as decoy receptors that counteract the proinflammatory processes triggered by the RAGE/ligand interaction12.
Serum levels of the RAGE ligands S100A12 and HMGB1 as well as the soluble RAGE forms sRAGE and 
esRAGE, have been shown to be differently regulated during chronic inflammatory diseases, and are proposed 
as correlates of disease severity and outcome19–21. The aim of the present study was to analyse the association 
between serum levels of sRAGE, esRAGE, S100A12 and HMGB1 and the extent of lung involvement assessed by 
Chest X-rays (CXR) in patients with smear positive PTB.
Results
Serum levels of S100A12 and sRAGE are differently regulated in PTB patients and healthy controls. 
(Table 1) portrays overall and analysis-specific characteristics of the 119 patients with PTB and the 163 healthy con-
trols. The cases were younger than the controls (26 ± 11 vs 32 ± 10 years, p < 0.0001) and had a lower BMI (16 ± 2.6 
vs 24 ± 4.5 kg/m2, p < 0.0001). There were no significant differences in gender between groups. The serum levels 
of sRAGE, esRAGE, S100A12, HMGB1 along with C-reactive protein (CRP) were assessed for association with 
PTB. After one initial comparison, different adjustments were done to the crude significance values according to 
the existing evidence regarding their relationship with PTB or with levels of sRAGE, esRAGE, S100A12, HMGB-1 
and CRP, respectively22–29. After adjustments, a higher frequency of patients with cigarette smoking and alco-
hol consumption could be found when compared to controls (0.21 ± 0.83 vs 0.07 ± 0.28 pack-years) and (19% vs 
2%), (p = 0.004 and < 0.0001) respectively. In addition, cases had lower systolic blood pressure (BP), (103 ± 15 vs 
123 ± 17 mm/Hg, p < 0.0001). As shown in (Table 1), CRP was higher in cases than in controls; in contrast the 
sRAGE serum level was lower in cases than in controls, while the serum levels of S100A12 and TNF-α were higher 
in cases than in controls. There were no crude or adjusted differences in the levels of IFN-γ , HMGB-1 and esRAGE 
(Table 1). These data suggest that, TNF-α , S100A12, sRAGE and CRP are associated with PTB.
S100A12 and CRP are independent predictors of PTB disease occurrence. In a next step, we used 
uni- and multivariable logistic regression analyses to evaluate whether the variables with significant adjusted 
differences could serve as independent predictors of disease occurrence. In the univariable models, serum levels 
Variable Case (n = 119) Control (n = 163) P value (Crude) P value (Adjusted)
Age mean (SD), (Years) 26 ± 11 32 ± 10 < 0.0001 —
Sex No. (%), male/female 58 (49)/61 (51) 82 (50)/81 (49) 0.81 —
BMI mean (SD), (Kg/m2) 16 ± 2.6 24 ± 4.5 < 0.0001 < 0.0001a
Smoking habits mean (SD), pack-year 0.21 ± 0.83 0.07 ± 0.28 0.043 0.004a
Drinking habits No. (%), (yes/no) 22 (19)/97 (81) 3 (2)/160 (98) < 0.0001 < 0.0001a
Fasting blood glucose mean (SD), (mg/dL) 97 ± 30 104 ± 30 0.06 —
Blood pressure mean (SD), (mm/Hg)
Systolic 103 ± 15 123 ± 17 < 0.0001 < 0.0001a,b
Diastolic 74 ± 10 80 ± 12 < 0.0001 0.97a,b
Cholesterol mean (SD), (mg/dL) 167 ± 27 183 ± 33 < 0.0001 0.73b
LDL mean (SD), (mg/dL) 104 ± 25 115 ± 25 < 0.0001 0.77b
HDL mean (SD), (mg/dL) 41 ± 8.8 43 ± 33 0.37 —
Tryglicerides mean (SD), (mg/dL) 112 ± 38 136 ± 80 0.003 0.87b
Creatinine mean (SD), (mg/dL) 0.91 ± 0.13 0.96 ± 0.17 0.005 0.77 b
CRP median (IQR), (mg/L) 6.74 ± 2.15 3.18 ± 3.23 < 0.0001 < 0.0001a,b,c,d,e
TNF-α mean (SD), (pg/mL) 13.4 ± 21.8 6.1 ± 20.4 0.004 0.02a,b,c,d,e
IFN-γ median (IQR), (pg/mL) 7.0 ± 18 3.7 ± 11 0.17 —
S100A12 mean (SD), (ng/mL) 2.332 ± 1.631 1.090 ± 1.050 < 0.0001 < 0.0001a,b,c,d,e
sRAGE mean (SD), (ng/mL) 0.74 ± 0.54 1.002 ± 0.563 < 0.0001 0.003a,b,c,d,e
esRAGE mean (SD), (ng/mL) 0.06 ± 0.15 0.07 ± 0.10 0.65 —
HMGB-1 median (IQR), (ng/mL) 3.3 ± 5.5 3.0 ± 5.6 0.67 —
Table 1.  Baseline characteristics, related parameters and serum levels of CRP, S100A12, sRAGE and 
HMGB-1 in TB cases and controls. Adjusted for: aAge, bBMI, cSmoking habits, dDrinking habits and eSystolic 
BP by binary logistic regression. (SD) standard deviation, (IQR) interquartile range.
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of CRP, S100A12, sRAGE and TNF-α , as well as age, BMI, systolic BP, and alcohol consumption were predictors 
of disease occurrence (Table 2). In the multivariable analysis only, serum CRP, S100A12, BMI and systolic BP 
remained significantly associated (Table 3). The serum levels of CRP and S100A12 suggested that as these two 
markers increased, so did the probability of being a PTB patient (Odds Ratio (OR) 3.61, 95%CI 2.008–6.488, 
p = < 0.0001) and (OR 1.873, 95%CI 1.212–2.891, p = 0.004) respectively (Table 3). In summary, PTB patients 
had increased serum levels of CRP and S100A12 and both parameters are independent predictors of disease 
occurrence.
Serum levels of CRP and S100A12 change longitudinally during DOTS treatment. To fur-
ther assess a causal relationship and to rule out confounding effects due to other unknown factors, we used a 
repeated measure analysis to determine whether serum CRP, and S100A12 change in conjunction with DOTS 
treatment at 0, 2, 4 and 6 months. As shown in (Fig. 1a) the serum levels of CRP significantly decreased after 2 
months of DOTS treatment (4.40 ± 0.99 mg/L) compared to the levels at the time of diagnosis (6.75 ± 2.13 mg/L, 
p < 0.0001). While S100A12 significantly decreased after 4 months (0.822 ± 1.196 ng/mL) compared to the levels 
at the time of diagnosis (1.262 ± 1.358 ng/mL, p < 0.0001) (Fig. 1b). Similarly, significant changes were observed 
in systolic BP and BMI values (Fig. 1c,d).
Patients with pulmonary TB showed higher neutrophil and lower lymphocyte counts; neutro-
phils were positive predictors of S100A12 serum levels. S100A12 is constitutively expressed by neu-
trophil granulocytes11 and several clinical studies have associated the serum levels of S100A12 with neutrophil 
activation and neutrophilic inflammation30,31. In order to evaluate whether the same pattern is present in PTB we 
measured the differential peripheral White Blood Cell (WBC) counts in a subgroup of TB cases and healthy con-
trols that had this value available in their clinical records and compared first the differences in total cell numbers 
between the two groups and secondly we assessed the association of S100A12 in serum with the different cells 
populations by linear regression analysis. As shown in (Fig. 2a), a significantly higher WBC count was observed 
in patients when compared to healthy controls. This was mainly due to the increase of neutrophils and mono-
cytes (Fig. 2b,c). In contrast, lymphocytes were decreased in PTB compared to controls (Fig. 2d). Next, we used 
univariable linear regression to show that neutrophil and eosinophil counts were positive predictors of S100A12 
serum levels (β values 0.265 and 9.421, p = 0.016 and p = 0.012, Table 4 models 4 and 5, respectively). In contrast 
the associations with the lymphocyte and monocyte counts did not reach statistical significance. A subsequent 
multivariable analysis revealed that only the neutrophil count remained as significant positive predictor of the 
S100A12 serum levels (β value 0.265, p = 0.016) (Table 4, model 6).
S100A12 is a positive predictor of the extent of alveolar infiltration in the CXR of patients with 
pulmonary TB. We recently developed an assessment scheme for grading disease severity in PTB by specifi-
cally considering the five CXR manifestations: lung involvement, alveolar infiltration, cavitation, lymphadenopa-
thy and pleural effusion, these CXR features were differently associated with Body Mass Index (BMI) and sputum 
smear positivity, and changed to a different extent after 6 months of treatment32. We used this same assessment 
Predictor β S.E P value Exp β (OR) 95%CI for Exp β 
Model 1 CRP 1.646 0.225 < 0.0001 5.186 3.336–8.063
Model 2 S100A12 0.681 0.108 < 0.0001 1.974 1.592–2.443
Model 3 sRAGE − 0.483 0.206 0.019 0.613 0.413–0.924
Model 4 TNF-α 0.019 0.007 0.010 1.024 1.005–1.034
Model 5 Age − 0.051 0.012 < 0.0001 0.954 0.927–0.973
Model 6 BMI − 0.650 0.073 < 0.0001 0.523 0.452–0.603
Model 7 Systolic BP − 0.081 0.011 < 0.0001 0.924 0.903–0.944
Model 8 Fasting blood glucose − 0.009 0.005 0.081 0.992 0.979–1.001
Model 9 Smoking habits − 0.566 0.319 0.076 1.763 0.943–3.291
Model 10 Drinking habits 2.487 0.629 < 0.0001 12.02 3.505–41.23
Table 2.  Univariable logistic regression analysis: predictors of disease occurrence. Models parameters: Model 
1 CRP: constant: − 8.20, − 2Log likelihood 185-Chi2 < 0.0001, Hosmer and lemeshow test < 0.0001, R2 (Cox 0.49 
and Nagelkerke 0.67). Model 2 S100A12: constant: − 1.42, − 2Log likelihood 328-Chi2 < 0.0001, Hosmer and 
lemeshow test 0.01, R2 (Cox 0.17 and Nagelkerke 0.23). Model 3 sRAGE: constant: 0.206, − 2Log likelihood 
405-Chi2 0.016, Hosmer and lemeshow test 0.64, R2 (Cox 0.019 and Nagelkerke 0.026). Model 4 TNF-α : constant: 
− 0.48, − 2Log likelihood 375-Chi2 0.016, Hosmer and lemeshow test 0.07, R2 (Cox 0.03 and Nagelkerke 0.04). 
Model 5 Age: constant: 1.17, − 2Log likelihood 392-Chi2 0.002, Hosmer and lemeshow test 0.82, R2 (Cox 0.06 
and Nagelkerke 0.08). Model 6 BMI: constant: 12.05, − 2Log likelihood 170.5-Chi2 < 0.0001, Hosmer and 
lemeshow test 0.88, R2 (Cox 0.55 and Nagelkerke 0.73). Model 7 Systolic BP: constant: 8.8, − 2Log likelihood 
312.1-Chi2 < 0.0001, Hosmer and lemeshow test 0.21, R2 (Cox 0.24 and Nagelkerke 0.33). Model 8 Fasting blood 
glucose: constant: 0.66, − 2Log likelihood 403.8-Chi2 0.048, Hosmer and lemeshow test 0.86, R2 (Cox 0.012 and 
Nagelkerke 0.017). Model 9 Smoking habits: constant: − 0.302, − 2Log likelihood 405-Chi2 0.032, Hosmer and 
lemeshow test 0.001, R2 (Cox 0.01 and Nagelkerke 0.02). Model 10 Drinking habits: constant: − 0.494, − 2Log 
likelihood 358-Chi2 < 0.0001, Hosmer and lemeshow test 0.001, R2 (Cox 0.08 and Nagelkerke 0.11).
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scheme to evaluate the association of these specific CXR features with CRP, S100A12, sRAGE and WBC using 
regression analysis. A univariable ordinal regression revealed that the monocyte count and serum S100A12 levels 
were positive predictors for the extent of alveolar infiltration (OR 1.01, 95%CI 1.00–1.01, p = 0.049) and (OR 1.37, 
95%CI 1.10–1.71, p = 0.005 respectively). Blood neutrophil count was also a positive predictor, but on the bor-
derline of statistical significance (OR 1.18, 95%CI 1.0–1.39, p = 0.050) (Table 5 models 1, 2 and 3, respectively). 
In contrast, only S100A12 levels were significantly associated with the extent of alveolar infiltration (OR 2.60, 
95%CI 1.35–5.00, p = 0.004) in a multivariable model (Table 5, model 4). Thus, our data implicate that S100A12 
independently predicts the extent of alveolar infiltration in the CXR of PTB patients. Furthermore, the probability 
of having infiltration in all four lung quadrants increases with rising S100A12 serum levels.
Discussion
Recent studies suggest that neutrophils play a central role in the inflammatory response that causes PTB lung 
pathology8. In accordance, the results of our study demonstrate that PTB was associated with an increase in the 
Predictor Β S.E P value Exp β (OR) 95%CI for Exp β 
CRP 1.289 0.299 < 0.0001 3.61 2.008–6.488
S100A12 0.608 0.299 0.042 1.837 1.022–3.305
sRAGE − 1.668 0.910 0.067 0.189 0.032–1.122
TNF-α 0.012 0.017 0.473 1.012 0.980–1.046
BMI − 0.608 0.143 < 0.0001 0.932 0.411–0.720
Systolic BP − 0.071 0.033 0.030 0.932 0.874–0.993
Table 3.  Multivariable logistic regression analysis: S100A12 and sRAGE are independent predictors of 
disease occurrence. Model parameters: constant: 14.32, − 2Log likelihood 42-Chi2 < 0.0001, Hosmer and 
lemeshow test 0.94, R2 (Cox 0.67 and Nagelkerke 0.92). Cases n = 110, Controls n = 160.
Figure 1. CRP, S100A12, systolic BP and BMI values change longitudinally during disease recovery under 
DOTS treatment. TB patients were followed up during the antibiotic treatment on average 6 months and the 
values of (a) CRP, (b) S100A12, (c) systolic BP and (d) BMI were compared over time at 0, 2, 4 and 6 months 
in those individuals for which the four measurements were available, significance was tested by Friedman and 
Wilcoxon signed rank tests in (a–c) and represented as the median ± interquartile range (IQR) or with repeated 
measure ANOVA with post hoc test in (d) and represented as mean ± standard deviation (SD). n = 28 in (a), 42 
in (b), 50 in (c) and 55 in (d) individuals per time point. Time interval is given in months.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:31798 | DOI: 10.1038/srep31798
serum concentration of S100A12, as well as with elevated blood neutrophil counts. Additionally, PTB was asso-
ciated with a decrease in sRAGE serum levels. Importantly, although S100A12 along with CRP independently 
predicted PTB disease occurrence, only the serum concentration of S100A12 served as a predictor of alveolar 
lung infiltration evaluated by CXR.
The association of the serum S100A12 concentration with the extent of alveolar infiltration suggests that 
increased S100A12 serum levels reflect the neutrophilic lung damage seen in PTB patients. This is in accordance 
with recent reports describing that active PTB is characterized by an exudative reaction progressing to tubercu-
lous pneumonia33. Also supporting this, serum levels of S100A12 and sRAGE are associated with other chronic 
pulmonary diseases such as chronic obstructive lung disease (COPD) and cystic fibrosis (CF), in which neutro-
phils are known to be considerably involved in the pulmonary inflammatory process and disease pathology34,35.
Considering the role of sRAGE in chronic inflammatory processes, decreased sRAGE serum levels were 
reported in COPD and rheumatoid arthritis patients30,31,36–41. Of note, in most chronic diseases decreased sRAGE 
is accompanied by an increase in S100A12 which is associated with disease severity19. Our results support the 
hypothesis that during active inflammation in PTB, neutrophil influx into the lung results in increased S100A12 
concentrations. Further that serum S100A12 concentration might serve as an indicator to assess the extent of 
Figure 2. TB patients have increased neutrophil counts and decreased lymphocyte counts in their 
peripheral blood when compared to healthy controls. (a) Total WBC, (b) Neutrophil count, (c) Monocyte 
count, (d) Lymphocyte count and (e) Eosinophil count. Data are presented as the median ± interquartile range 
(IQR) and significance was tested with Mann Whitney U tests. n = 51 for cases and 43 for controls.
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pulmonary inflammation. In longitudinal studies of lung injury, sRAGE and S100A12 serum levels returned to 
control levels after disease recovery31,42. Similarly in our study S100A12 serum levels returned to normal values 
during DOTS therapy. This normalization of S100A12 was accompanied by a concurrently increasing BMI, likely 
reflecting the improvement of the patient’s general condition during treatment43.
Recent evidence highlights the association of S100 proteins with neutrophil associated inflammation and 
their role as potential surrogate markers to assess lung inflammation and disease severity in PTB44. S100A8/A9 
protein dimer is present in the inflammatory lung granulomas in active human PTB and in the TB mouse model 
these proteins mediate neutrophilic accumulation by inducing production of proinflammatory chemokines and 
cytokines44. Accordingly, our results not only suggest that neutrophils are the source of S100A12 but also that this 
protein is a predictor of alveolar infiltration, and we have recently shown that alveolar infiltration is associated 
with severity and infectivity in PTB32. Importantly, we measured CRP, a classical acute phase protein and indica-
tor of immune system activity, although we found that CRP is a good predictor of disease occurrence, the serum 
concentration of this protein was not associated with any radiographic abnormality. These results are in line with 
a study that found no correlation between CRP and CXR abnormalities in PTB45. Thus, while CRP is produced 
in the liver and is a well-known marker of systemic inflammation46, S100A12 might provide information about 
lung inflammation that is different to systemic inflammation expressed by CRP. Alveolar infiltration might lead to 
scaring and long term pulmonary affection which could be preventable47. Accordingly, a recent systematic review 
found that TB is strongly associated with the presence of chronic respiratory disease in adults in TB endemic 
areas, highlighting the need for actions to improve long-term lung health in TB care and surrogate markers to 
assess lung involvement and damage48. Of note, we found no association between neutrophil counts and alveolar 
infiltration. During infection more than one-half of the neutrophils in the peripheral circulation are attached to 
Predictor Β S.E P value 95%CI for β 
Model 1 WBC 0.240 0.078 0.011 0.068–0.412
Model 2 
Neutrophils 0.265 0.094 0.016 0.059–0.470
Model 3 
Monocytes 7.945 3.947 0.069 − 0.742–16.63
Model 4 
Lymphocytes 0.975 0.474 0.064 − 0.069–2.019
Model 5 
Eosinophils 9.421 4.126 0.012 2.541–16.32
Multivariable
Model 6 
Neutrophils 0.265 0.094 0.016 0.059–0.470
Table 4.  Univariable and multivariable linear regression analysis: neutrophils are positive predictors 
of S100A12 serum levels. Models parameters: Model 1: WBC. Constant 867, ANOVA 0.011, R2 0.41. Model 
2: Neutrophils. Constant 1417, ANOVA 0.016, R2 0.36. Model 3: Monocytes. Constant 1596, ANOVA 0.069, 
R2 0.20. Model 4: Lymphocytes. Constant 607, ANOVA 0.064, R2 0.21. Model 5: Eosinophils. Constant 
1614, ANOVA 0.012, R2 0.40. Model 6: Constant 1417, ANOVA 0.016, R2 0.36. Other variables in model 6: 
Lymphocytes, monocytes, eosinophils.
Predictor Β S.E P value Exp. β (OR) 95% for Exp. β (OR)
Model 1 
Neutrophils 0.165 0.084 0.050 1.18 1.00–1.39
Model 2 
Monocytes 0.007 0.003 0.049 1.01 1.00–1.01
Model 3 
S100A12 0.317 0.112 0.005 1.37 1.10–1.71
Multivariable
  Model 4 
Neutrophils − 0.106 0.228 0.643 0.90 0.58–1.41
 Monocytes 0.011 0.010 0.272 1.01 0.99–1.03
 S100A12 0.956 0.333 0.004 2.60 1.35–5.00
Table 5.  Univariable and multivariable ordinal regression: S100A12 is a positive predictor for the extent 
of alveolar infiltration in the CXR of patients with pulmonary TB. Dependent ordinal variable alveolar 
infiltration (None, 1 quadrant, 2 quadrants, 3 quadrants and 4 quadrants). Models parameters: Model 1 − 2Log 
128 Chi2 0.052, Goodness of fit 0.47, Pseudo R2 (Cox and snell 0.075, Nagelkerke 0.081), test of parallel lines 
0.516; n = 51. Model 2 − 2Log 118 Chi2 0.051, Goodness of fit 0.66, Pseudo R2 (Cox and snell 0.076, Nagelkerke 
0.081), test of parallel lines 0.490; n = 51 Model 3 − 2Log 295 Chi2 0.005, Goodness of fit 0.79, Pseudo R2 (Cox 
and snell 0.068, Nagelkerke 0.073), test of parallel lines 0.089; n = 112. Model 4 − 2Log 70 Chi2 0.002, Goodness 
of fit 0.83, Pseudo R2 (Cox and snell 0.39, Nagelkerke 0.42), test of parallel lines 0.47; n = 51. Reference category: 
alveolar infiltration 4 quadrants.
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the vascular endothelium49. As these cells migrate across the endothelium to inflammatory foci, they get acti-
vated; generate free radicals, and release granule contents and inflammatory mediators such as calgranulins50. 
Our data suggest that an association between neutrophil count and alveolar infiltration might exist but the results 
did not reach statistical significance and it could be explained by the small sample size because the neutrophil 
count was available only for 51 TB patients. However, although an association between neutrophil count and 
alveolar infiltration could not be ruled out, our results demonstrate that the association with S100A12 is stronger.
One limitation of our study is that although all the individuals used as controls were clinically healthy at the 
moment of sample collection, we are not certain about their status in terms of past exposure to M. tuberculosis 
or latency. Thus some might differ in their latency status what could eventually affect the results. In addition, we 
followed up the patients only for 6 months what does not allow assessment of any associations with long term 
outcome. In this study we reveal an association of S100A12 with lung involvement in PTB, however, similar asso-
ciations have been shown with other inflammatory diseases19, thus, future studies should address the comparison 
of this immune marker across different pulmonary diseases.
Our findings suggest that the measurement of S100A12 serum concentration may help to stratify the extent 
of alveolar infiltration of PTB patients at the time of diagnosis, to identify cases that would benefit from strategies 
to avoid long-term lung impartment. This research has laid the ground work for further evaluate the potential 
application of serum S100A12 and S100 proteins for the assessment of lung involvement in patients with PTB
In conclusion our results highlight the role of neutrophils in the pathogenesis of smear positive PTB and 
demonstrate that S100A12 could serve as a novel target to assess the extent of alveolar infiltration in patients with 
PTB. Therefore the role of this molecule as biomarker for TB should be more accurately defined.
Materials and Methods
Study design, setting and participants. We carried out a cross sectional cohort and a self-controlled 
case series study in Mahavir hospital and Research Center in Hyderabad, India. For the purpose of calculating 
sample size, a pilot survey was performed with 25 TB patients and 15 healthy controls in March 2011. Our calcu-
lations indicated that, 94 and 45 individuals per group would be required for sRAGE and S100A12 respectively, to 
detect a significant difference according to the observed effect sizes and the influence of the potential confounders 
and effect modifiers with 80% power and 5% significance level. However more individuals were included to allow 
for missing data. The final recruitment period (July 26 2011- July 25 2013) resulted in a final sample size of 119 
PTB patients and 163 healthy controls.
Criteria for inclusion as a case were: newly diagnosed pulmonary sputum smear positive TB disease and treat-
ment naïve patients who entered the Hyderabad Directly Observed Treatment, Short-course (DOTS) program at 
Mahavir hospital. The diagnostic criterion for PTB was defined as the presence of one of the following: at least 2 
initial sputum smear examinations positive for Acid-Fast Bacilli (AFB) or sputum examination positive for AFB 
and radiographic abnormalities consistent with active pulmonary TB51.
Criteria for inclusion as healthy control were: absence of apparent acute or chronic pulmonary diseases or 
diseases of other origin, and a negative history of TB disease. All healthy control individuals were from the same 
geographical origin, living in Hyderabad and were clinically in good health at the time of sample collection. 
Individuals with signs and symptoms suggesting active PTB or a history of prior anti-TB treatment were excluded 
from the study. All study participants gave written informed consent and the study was approved by the institu-
tional ethics committee for bio-medical research at the Bhagwan Mahavir Medical Research Centre, Hyderabad, 
India. The methods used in this study were in accordance with the approved guidelines.
End points, follow-up and variables. All PTB patients were prospectively followed up on average for 6 
months from the beginning to the end of the treatment. The final end points were: death, loss to follow-up and 
end of therapy. The demographic data, including gender, age and BMI along with other relevant clinical data were 
recorded using the standard hospital’s DOTS program questionnaire. The main potential confounders and effect 
modifiers were: age, gender, BMI, blood glucose, smoking, alcohol consumption, HIV infection, blood pressure, 
lipid profile (cholesterol, Low Density Lipoprotein (LDL) and triglycerides), chronic kidney disease, cardiovas-
cular disease and use of lipid lowering drugs which have been related to the risk of getting TB or to influence the 
levels of S100A12, sRAGE and esRAGE in serum23,24,26,52. The final treatment outcome was recorded as cured, 
died, failure or defaulted according to the India technical and operational guidelines for TB control51.
Data sources and measurements. The demographic data were obtained directly from patients or their 
relatives and healthy individuals during an interview performed by a trained researcher at initial recruitment. 
Smoking and alcohol consumption were self-reported and assessed by including these questions into the standard 
DOTS questionnaire according to previously described53,54. Other relevant clinical data were obtained from the 
hospital’s TB control program records and medical staff. The blood pressure was measured with the MX2 digital 
automatic blood pressure monitor (Omron GmbH, Mannheim-Germany) and one peripheral blood sample was 
obtained after overnight fasting from healthy controls at initial recruitment and from TB patients at the start of 
therapy and after 2, 4 and 6 months. The serum was isolated and stored at − 20 °C.
Complete peripheral blood count, lipid profile (total cholesterol, LDL cholesterol, triglycerides and HDL cho-
lesterol) and creatinine were analysed by the hospital pathology service using Sysmex KX-21 blood analyser 
(Sysmex, Kone-Japan) and Konelab 20 clinical chemistry analyzer (Thermo scientific, Rockford, Illinois- USA) 
respectively. Fasting blood glucose was measured using the Accu-Chek Performa (Roche Diagnostics GmbH, 
Mannheim-Germany). Immune markers were determined with commercially available ELISA kits as fol-
lows: sRAGE (R&D systems, Minneapolis, Minnesota-USA), esRAGE (B-Bridge International, Tokyo-Japan), 
HMGB-1 (IBL international GmbH, Hamburg-Germany), S100A12/EN-RAGE (MBL international, Woburn, 
Massachusetts-USA), CRP (Thermo scientific), TNF-(α ) and IFN-(γ ) (BD biosciences, Heidelberg-Germany).
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Chest radiography. A CXR analysis was performed to every recruited patient at the time of diagnosis 
using a Siemens Heliophos D X-rays generator (Siemens, Mumbai-India). The CXR were evaluated as previously 
described32.
Statistical methods. Normally distributed variables were expressed as mean ± SD, not normally distrib-
uted variables as median ± interquartile range, and statistical differences between two groups were analysed 
using a two-sided Student’s t test or a Mann Whitney U test. One way ANOVA with post hoc test or Kruskall 
Wallis and Mann Whitney U test with Bonferrini adjustment were used for normally and not normally distrib-
uted variables when more than two groups were compared. Binary logistic regression was used for adjustments 
for potential confounders in the cross sectional associations and for assessing predictors of disease occurrence. 
Univariable logistic regression models were done and those variables found to be predictors of disease occurrence 
were then analysed with hierarchical multivariable and backwards Likelihood Ratio (LR) regression models. 
Hosmer-Lemeshow goodness of fit test was used as goodness of fit for model fitting assessment and VIF values 
were used to assess multicollinearity. The best fitting models were chosen by analysing the change in the LR sta-
tistic after different variables were included or removed from the model. Cox & Snell and Nagelkerke R squares 
were reported to assess the proportion of variance explained by the predictors and different models. The longitu-
dinal data were analyzed with repeated measures ANOVA with post hoc test or with Friedman test and Wilcoxon 
signed rank test for normally and not normally distributed variables respectively.
Linear regression was used to analyse the association of S100A12 with peripheral blood cell counts. In linear 
regression analysis ANOVA test was used as goodness of fit for model fitting assessment and the R2 test to assess 
the proportion of variance explained by the predictors. In linear and logistic regressions, deviance and partial 
residuals were used to identify potential outliers influencing the models. The association of alveolar infiltration 
and immune markers was assessed with univariable and multivariable ordinal regression analysis: the goodness 
of fit test was used for model fitting assessment, the amount of variation explained by the model with pseudo R2 
and the proportional odds assumption was assessed with the test of parallel lines. SPSS 21 (SPSS Inc., Chicago, 
Illinois USA) was used for data analysis and values of p < 0.05 were considered significant. Graphics were done 
with GraphPad Prism Software version 5.00 for Windows (GraphPad Software, San Diego California, USA) and 
sample size and power calculations with OpenEpi version 3.01. The STROBE guideline was used to guide the 
report of this observational study.
References
1. World Health Organization (WHO). Global tuberculosis report (2014) (Date of access:15/04/2015) Available in: http://www.who.int/
tb/publications/global_report/gtbr14_main_text.pdf?ua= 1.
2. Hunter, R. L. Pathology of post primary tuberculosis of the lung: an illustrated critical review. Tuberculosis (Edinb) 91, 497–509, doi: 
10.1016/j.tube.2011.03.007 (2011).
3. Lawn, S. D. & Zumla, A. I. Tuberculosis. Lancet 378, 57–72, doi: 10.1016/S0140-6736(10)62173-3 (2011).
4. Chung, K. P. et al. Trends and predictors of changes in pulmonary function after treatment for pulmonary tuberculosis. Clinics  
(Sao Paulo) 66, 549–556 (2011).
5. Hnizdo, E., Singh, T. & Churchyard, G. Chronic pulmonary function impairment caused by initial and recurrent pulmonary 
tuberculosis following treatment. Thorax 55, 32–38 (2000).
6. World Health Organization (WHO). Treatment of tuberculosis guidelines 4th ed (2010), (Date of access:15/03/2015)Available in: 
http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833_eng.pdf?ua= 1&ua= 1.
7. Marais, B. J. et al. Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. 
Lancet 375, 2179–2191, doi: 10.1016/S0140-6736(10)60554-5 (2010).
8. Lowe, D. M., Redford, P. S., Wilkinson, R. J., O’Garra, A. & Martineau, A. R. Neutrophils in tuberculosis: friend or foe? Trends 
Immunol 33, 14–25, doi: 10.1016/j.it.2011.10.003 (2012).
9. Desvignes, L. & Ernst, J. D. Interferon-gamma-responsive nonhematopoietic cells regulate the immune response to Mycobacterium 
tuberculosis. Immunity 31, 974–985, doi: 10.1016/j.immuni.2009.10.007 (2009).
10. Nandi, B. & Behar, S. M. Regulation of neutrophils by interferon-gamma limits lung inflammation during tuberculosis infection. 
J Exp Med 208, 2251–2262, doi: 10.1084/jem.20110919 (2011).
11. Pietzsch, J. & Hoppmann, S. Human S100A12: a novel key player in inflammation? Amino Acids 36, 381–389, doi: 10.1007/s00726-
008-0097-7 (2009).
12. Bierhaus, A. et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 83, 876–886, doi: 
10.1007/s00109-005-0688-7 (2005).
13. Han, S. H., Kim, Y. H. & Mook-Jung, I. RAGE: the beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells 31, 
91–97, doi: 10.1007/s10059-011-0030-x (2011).
14. Hofmann, M. A. et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin 
polypeptides. Cell 97, 889–901 (1999).
15. Galichet, A., Weibel, M. & Heizmann, C. W. Calcium-regulated intramembrane proteolysis of the RAGE receptor. Biochem Biophys 
Res Commun 370, 1–5, doi: 10.1016/j.bbrc.2008.02.163 (2008).
16. Raucci, A. et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of 
the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22, 3716–3727, doi: 10.1096/
fj.08-109033 (2008).
17. Yamakawa, N., Uchida, T., Matthay, M. A. & Makita, K. Proteolytic release of the receptor for advanced glycation end products from 
in vitro and in situ alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 300, L516–L525, doi: 10.1152/ajplung.00118.2010 
(2011).
18. Zhang, L. et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. 
J Biol Chem 283, 35507–35516, doi: 10.1074/jbc.M806948200 (2008).
19. Meijer, B., Gearry, R. B. & Day, A. S. The role of S100A12 as a systemic marker of inflammation. Int J Inflam 2012, 907078, doi: 
10.1155/2012/907078 (2012).
20. Christaki, E., Lazaridis, N. & Opal, S. M. Receptor for advanced glycation end products in bacterial infection: is there a role for 
immune modulation of receptor for advanced glycation end products in the treatment of sepsis? Curr Opin Infect Dis 25, 304–311, 
doi: 10.1097/QCO.0b013e3283519b82 (2012).
21. Iwamoto, H. et al. Soluble receptor for advanced glycation end-products and progression of airway disease. BMC Pulm Med 14, 68, 
doi: 10.1186/1471-2466-14-68 (2014).
www.nature.com/scientificreports/
9Scientific RepoRts | 6:31798 | DOI: 10.1038/srep31798
22. Narasimhan, P., Wood, J., Macintyre, C. R. & Mathai, D. Risk factors for tuberculosis. Pulm Med 2013, 828939, doi: 10.1155/2013/828939 
(2013).
23. Faheem, M. et al. Does BMI affect cholesterol, sugar, and blood pressure in general population? J Ayub Med Coll Abbottabad 22, 
74–77 (2010).
24. Gerchman, F. et al. Body mass index is associated with increased creatinine clearance by a mechanism independent of body fat 
distribution. J Clin Endocrinol Metab 94, 3781–3788, doi: 10.1210/jc.2008-2508 (2009).
25. Selvin, E. et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 62, 2116–2121, doi: 10.2337/db12-1528 
(2013).
26. Koyama, H. et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and 
atherosclerosis. Arterioscler Thromb Vasc Biol 25, 2587–2593, doi: 10.1161/01.ATV.0000190660.32863.cd (2005).
27. Timpson, N. J. et al. C-reactive protein levels and body mass index: elucidating direction of causation through reciprocal Mendelian 
randomization. Int J Obes (Lond) 35, 300–308, doi: 10.1038/ijo.2010.137 (2011).
28. Tonstad, S. & Cowan, J. L. C-reactive protein as a predictor of disease in smokers and former smokers: a review. Int J Clin Pract 63, 
1634–1641, doi: 10.1111/j.1742-1241.2009.02179.x (2009).
29. Wener, M. H., Daum, P. R. & McQuillan, G. M. The influence of age, sex, and race on the upper reference limit of serum C-reactive 
protein concentration. J Rheumatol 27, 2351–2359 (2000).
30. Foell, D. et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. 
Rheumatology (Oxford) 42, 1383–1389, doi: 10.1093/rheumatology/keg385 (2003).
31. Foell, D. et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum 
50, 1286–1295, doi: 10.1002/art.20125 (2004).
32. Grozdanovic, Z. et al. A Novel Reading Scheme for Assessing the Extent of Radiographic Abnormalities and Its Association with 
Disease Severity in Sputum Smear-Positive Tuberculosis: An Observational Study in Hyderabad/India. PLoS One 10, e0138070, doi: 
10.1371/journal.pone.0138070 (2015).
33. Hunter, R. L., Actor, J. K., Hwang, S. A., Karev, V. & Jagannath, C. Pathogenesis of post primary tuberculosis: immunity and 
hypersensitivity in the development of cavities. Ann Clin Lab Sci 44, 365–387 (2014).
34. Gifford, A. M. & Chalmers, J. D. The role of neutrophils in cystic fibrosis. Curr Opin Hematol 21, 16–22, doi: 10.1097/
MOH.0000000000000009 (2014).
35. Bozinovski, S., Anthony, D. & Vlahos, R. Targeting pro-resolution pathways to combat chronic inflammation in COPD. J Thorac Dis 
6, 1548–1556, doi: 10.3978/j.issn.2072-1439.2014.08.08 (2014).
36. Cockayne, D. A. et al. Systemic biomarkers of neutrophilic inflammation, tissue injury and repair in COPD patients with differing 
levels of disease severity. PLoS One 7, e38629, doi: 10.1371/journal.pone.0038629 (2012).
37. Smith, D. J. et al. Reduced soluble receptor for advanced glycation end-products in COPD. Eur Respir J 37, 516–522, doi: 
10.1183/09031936.00029310 (2011).
38. Sukkar, M. B. et al. Soluble RAGE is deficient in neutrophilic asthma and COPD. Eur Respir J 39, 721–729, doi: 
10.1183/09031936.00022011 (2012).
39. Myles, A., Viswanath, V., Singh, Y. P. & Aggarwal, A. Soluble receptor for advanced glycation endproducts is decreased in patients 
with juvenile idiopathic arthritis (ERA category) and inversely correlates with disease activity and S100A12 levels. J Rheumatol 38, 
1994–1999, doi: 10.3899/jrheum.110058 (2011).
40. Pullerits, R., Bokarewa, M., Dahlberg, L. & Tarkowski, A. Decreased levels of soluble receptor for advanced glycation end products 
in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 7, R817–R824, doi: 10.1186/
ar1749 (2005).
41. Miniati, M. et al. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor 
pulmonale: a case-control study. Respir Res 12, 37, doi: 10.1186/1465-9921-12-37 (2011).
42. Jabaudon, M. et al. Soluble form of the receptor for advanced glycation end products is a marker of acute lung injury but not of 
severe sepsis in critically ill patients. Crit Care Med 39, 480–488, doi: 10.1097/CCM.0b013e318206b3ca (2011).
43. Sanchez, A., Azen, C., Jones, B., Louie, S. & Sattler, F. Relationship of Acute Phase Reactants and Fat Accumulation during Treatment 
for Tuberculosis. Tuberc Res Treat 2011, 346295, doi: 10.1155/2011/346295 (2011).
44. Gopal, R. et al. S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis. Am J Respir Crit 
Care Med 188, 1137–1146, doi: 10.1164/rccm.201304-0803OC (2013).
45. Mendy, J. et al. C-reactive protein, Neopterin and Beta2 microglobulin levels pre and post TB treatment in The Gambia. BMC Infect 
Dis 16, 115, doi: 10.1186/s12879-016-1447-9 (2016).
46. Wu, Y., Potempa, L. A., El Kebir, D. & Filep, J. G. C-reactive protein and inflammation: conformational changes affect function. Biol 
Chem 396, 1181–1197, doi: 10.1515/hsz-2015-0149 (2015).
47. O’Toole, R. F., Shukla, S. D. & Walters, E. H. TB meets COPD: An emerging global co-morbidity in human lung disease. Tuberculosis 
(Edinb) 95, 659–663, doi: 10.1016/j.tube.2015.08.005 (2015).
48. Byrne, A. L., Marais, B. J., Mitnick, C. D., Lecca, L. & Marks, G. B. Tuberculosis and chronic respiratory disease: a systematic review. 
Int J Infect Dis 32, 138–146, doi: 10.1016/j.ijid.2014.12.016 (2015).
49. Nourshargh, S. & Alon, R. Leukocyte migration into inflamed tissues. Immunity 41, 694–707, doi: 10.1016/j.immuni.2014.10.008 
(2014).
50. Boussac, M. & Garin, J. Calcium-dependent secretion in human neutrophils: a proteomic approach. Electrophoresis 21, 665–672, 
doi: 10.1002/(SICI)1522-2683(20000201)21:3< 665::AID-ELPS665> 3.0.CO;2-U (2000).
51. Central T. B. Division, Directorate General of Health Services & Ministry of Health India. Technical and operational guidelines for 
Tuberculosis control (2005) (Date of access:15/02/2011)Available in: http://tbcindia.nic.in/pdfs/Technical%20&%20Operational%20
guidelines%20for%20TB%20Control.pdf.
52. Cegielski, J. P. & McMurray, D. N. The relationship between malnutrition and tuberculosis: evidence from studies in humans and 
experimental animals. Int J Tuberc Lung Dis 8, 286–298 (2004).
53. Greenfield, T. K. & Kerr, W. C. Alcohol measurement methodology in epidemiology: recent advances and opportunities. Addiction 
103, 1082–1099, doi: 10.1111/j.1360-0443.2008.02197.x (2008).
54. Prignot, J. Quantification and chemical markers of tobacco-exposure. Eur J Respir Dis 70, 1–7 (1987).
Acknowledgements
German Research Foundation (DFG) and the Federal Ministry of Education and Research (BMBF).
Author Contributions
Conceived and designed the experiments: L.C.B.A. and H.S. Performed the experiments: L.C.B.A., S.G., A.H., 
G.S., T.E.K., M.L.C. and N.D. Analyzed the data: L.C.B.A., Z.G., B.L., T.E.K., D.D. and H.S. Contributed reagents/
materials/analysis tools: R.R.S., G.S., V.V. and N.A. Wrote the paper: L.C.B.A. and H.S.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:31798 | DOI: 10.1038/srep31798
Additional Information
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Berrocal-Almanza, L. C. et al. S100A12 is up-regulated in pulmonary tuberculosis and 
predicts the extent of alveolar infiltration on chest radiography: an observational study. Sci. Rep. 6, 31798;  
doi: 10.1038/srep31798 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
 
© The Author(s) 2016
